MedPath

Primary Versus Deferred Ureteroscopy for Calculus Anuria in Children

Not Applicable
Conditions
Ureter Obstruction
Registration Number
NCT04980079
Lead Sponsor
South Valley University
Brief Summary

To evaluate the role of both primary and deferred URS in the management of calculus anuria concerning the feasibility, clinical outcome, and cost-effectiveness in children in a comparative study

Detailed Description

Thirty group B (30) patients will be admitted to do urinary drainage through the insertion of a JJ stent or percutaneous nephrostomy (PCN) at first , then a deferred URS will be done children will undergo primary URS( group A ) and in. Ureteral dilatation will be done when the stone size exceeds 10 mm to facilitate the extraction of the fragments. Ureteroscopic lithotripsy will be done using a 6.5:7.5 Fr semi-rigid ureteroscope and holmium laser. The ureteric stent will last for one week after lithotripsy. Postoperatively, the patients in both groups will monitored for post obstructive diuresis, fever, hematuria, and extent of renal function improvement.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Children ˂12 years with calculus anuria.
  • Clinically stable (serum creatinine < 3.5 mg/dl, blood urea < 100 mg/dl,serum potassium level < 7 milliequivalent /L and /or ph of blood > 7.1)
  • All the patients free of sepsis.
Exclusion Criteria
  • Unstable children (serum creatinine ≥ 3.5 mg/dl, blood urea ≥ 100 mg/dl, serum potassium ≥ 7 milliequivalent/l, and/or blood pH ≤ 7.1, signs of acidosis, sepsis, or fluid retention).
  • Children with underlying urological structural abnormalities

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
renal functionone month .

improvement in creatinine level mg/dl urea level mg/dl

Secondary Outcome Measures
NameTimeMethod
the stone-free ratesone month

The clinical outcomes of the procedures including the perioperative complications :

* of perforation

* of infection

* of residual stones

* of the stone-free rates

Trial Locations

Locations (1)

Mostafa

🇪🇬

Luxor, Egypt

Mostafa
🇪🇬Luxor, Egypt
Mostafa Mostafa, B.sc
Contact
01069432827
mostafaalsoghier@yahoo.com
asmaa mostafa, MD
Contact
010144437474
lalamohamed@yahoo.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.